E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients who undergo esophagogastroduodenoscopy procedure for a first time |
Potilaat, joille tehdään ensimmäistä kertaa mahalaukun tähytystoimenpide |
|
E.1.1.1 | Medical condition in easily understood language |
Impared digestion
Heartburn
Bloody vomiting
Vomiting
Abdominal pain
Black stool |
Närästys
Oksentelu
Verioksentelu
Vatsakipu
Veriulosteet
Imeytymishäiriö
|
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014819 |
E.1.2 | Term | Endoscopy upper gastrointestinal tract |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to examine in prospective, double-blinded randomised manner the ability of novel articaine-containing lozenge (2% and 1%) to enhance the procedure related compliance (compared to placebo) of the adult patients undergoing upper gastrointestinal endoscopy |
Tutkimuksen tarkoitus on on selvittää parantaako 2% ja 1% artikaiinikurlausliuos verrattuna lumeeseen potilaiden tyytyväisyyttä tähystystoimenpiteeseen ja potilaiden yhteistyökykyä toimenpiteen aikana |
|
E.2.2 | Secondary objectives of the trial |
Endoscopists´ procedural satisfaction assessed within 30 minutes after the procedure |
Toimenpidelääkärin tyytyväisyys toimenpiteen kulun sujuvuuteen arvioituna toimenpiteen jälkeen |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-elective procedure
-weight over 40 kg
-American Society of Anesthesiology class I-III
-first upper GI endoscopy procedure
-finnish or/and swedish
speaking
- age 20-75
- both gender |
|
E.4 | Principal exclusion criteria |
-amide and/or esther local anaesthetic allergy
-paraben allergy
-Child-Pugh grade B/C liver failure
-renal insufficiency (calculated glomerular filtration rate under 60 ml/min/1.73 m2 according to Cockcroft-Gault scale )
-dementia
-those presenting with swallowing problem
-chronic pain condition
-chronic use of pain medication
-pregnancy
-lactation |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage of participants with 15% change in tolerability points according to Visual Analogue Scale (compared to baseline Visual Analogue Scale) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Endoscopists´ procedural satisfaction points after the procedure assessed by using Visual Analogue Scale (VAS).
Cumulative consumption of alfentanil during the procedure (mg) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |